In the present study, we found that the intranasal administration of BMP9 significantly reduced the amyloid plaque load and Aβ levels in the brains of APP/PS1 mice, probably by promoting the efflux of Aβ mediated by LRP1. The gene discussed is APP; the disease is amyloidosis.